For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.
Angela Weiss | AFP | Getty Images
The cost of GLP-1 drugs is falling, and pill versions are hitting the U.S. market. For restaurant chains and snacking giants, higher adoption of weight loss and diabetes treatments poses a threat to their sales — or ... [11782 chars]